These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9799354)

  • 1. The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients.
    de Bree R; Kuik DJ; Quak JJ; Roos JC; van den Brekel MW; Castelijns JA; van Wagtendonk FW; Greuter H; Snow GB; van Dongen GA
    Eur J Nucl Med; 1998 Nov; 25(11):1562-5. PubMed ID: 9799354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
    de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
    Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
    Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
    Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in radioimmunotherapy of head and neck-cancer (review).
    Vandongen G; Brakenhoff R; Debree R; Gerretsen M; Quak J; Snow G
    Oncol Rep; 1994 Jan; 1(1):259-64. PubMed ID: 21607350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.
    de Bree R; Roos JC; Plaizier MA; Quak JJ; van Kamp GJ; den Hollander W; Snow GB; van Dongen GA
    Br J Cancer; 1997; 75(7):1049-60. PubMed ID: 9083342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
    Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
    Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer.
    de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA
    Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck.
    Schrijvers AH; Quak JJ; Uyterlinde AM; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Cancer Res; 1993 Sep; 53(18):4383-90. PubMed ID: 8364934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
    Colnot DR; Roos JC; de Bree R; Wilhelm AJ; Kummer JA; Hanft G; Heider KH; Stehle G; Snow GB; van Dongen GA
    Cancer Immunol Immunother; 2003 Sep; 52(9):576-82. PubMed ID: 14627130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract.
    De Bree R; Roos JC; Quak JJ; Den Hollander W; Snow GB; Van Dongen GA
    Nucl Med Commun; 1994 Aug; 15(8):613-27. PubMed ID: 7970443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
    Verel I; Visser GW; Vosjan MJ; Finn R; Boellaard R; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
    Hauck ML; Zalutsky MR
    Int J Hyperthermia; 2005 Feb; 21(1):1-11. PubMed ID: 15764347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer.
    van Gog FB; Brakenhoff RH; Stigter-van Walsum M; Snow GB; van Dongen GA
    Int J Cancer; 1998 Jul; 77(1):13-8. PubMed ID: 9639387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The feasibility of radioimmunotherapy of head and neck cancer.
    Gerretsen M; Quak JJ; Brakenhoff RH; Snow GB; van Dongen GA
    Eur J Cancer B Oral Oncol; 1994; 30B(2):82-7. PubMed ID: 8032305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
    van Gog FB; Visser GW; Stroomer JW; Roos JC; Snow GB; van Dongen GA
    Cancer; 1997 Dec; 80(12 Suppl):2360-70. PubMed ID: 9406684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
    Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.